Patient preference doesn't affect chemo in advanced CRC

Patient preference doesn't affect chemo in advanced CRC
For patients with metastatic colorectal cancer, most patients are treated with chemotherapy, even if they express negative or marginal preferences, according to a study published online Sept. 12 in Cancer.

(HealthDay)—For patients with metastatic colorectal cancer (mCRC), most patients are treated with chemotherapy, even if they express negative or marginal preferences, according to a study published online Sept. 12 in Cancer.

S. Yousuf Zafar, M.D., M.H.S., of the Duke Cancer Institute in Durham, N.C., and colleagues conducted a involving 702 patients with mCRC to determine how patient preferences guide the course of palliative .

Overall, 91 percent of patients were treated by a medical oncologist, and 82 percent of these received chemotherapy. The researchers found that patients aged 65 to 75 years or 75 years and older were less likely to visit an oncologist, as were those who were too unwell to complete their own survey. Patients who were 75 years or older with moderate or severe comorbidities or patients who were too unwell to complete their own survey were less likely to receive chemotherapy. Patients tended to receive chemotherapy even when they felt that treatment would not extend their lives (90 percent) or help them with their cancer-related problems (89 percent), and even when they stated a preference to focus on comfort rather than extending their life (90 percent).

"In summary, in the palliative setting were not always congruent with stated preferences and beliefs regarding chemotherapy," the authors write. "The vast majority of patients who expressed negative or marginal preferences or beliefs regarding chemotherapy still received chemotherapy. Patient preferences and beliefs were not associated with the intensity or number of chemotherapy regimens received."

Several authors disclosed financial ties to the .

More information: Abstract
Full Text (subscription or payment may be required)

add to favorites email to friend print save as pdf

Related Stories

Recommended for you

Endogenous hormones improve breast cancer risk models

22 hours ago

(HealthDay)—Inclusion of endogenous hormones in prediction models improves prediction of invasive breast cancer risk in postmenopausal women, according to a study published online Aug. 18 in the Journal of ...

Novel oncogenic RET mutation found in small cell lung cancer

23 hours ago

For the first time an oncogenic somatic mutation at amino acid 918 in the RET (rearranged during transfection) protein has been identified in small cell lung cancer (SCLC) tumors and enforced expression of this mutation within ...

User comments